The Experts below are selected from a list of 72 Experts worldwide ranked by ideXlab platform
Galindo Ramos, Paula Andrea - One of the best experts on this subject based on the ideXlab platform.
-
Reacciones adversas com Misoprostol reportadas al Programa Mundial de Farmacovigilancia de la OMS 1985-2019
Bogotá : Universidad de Ciencias Aplicadas y Ambientales 2020, 2020Co-Authors: Ferro Holguín, Laura Natalia, Galindo Ramos, Paula AndreaAbstract:97 páginas : gráficasEl misoprostol es un análogo sintético de la prostaglandina E1, el cual tiene varias indicaciones terapéuticas (1), en algunos países se utiliza como antiulceroso para prevenir úlceras gástricas inducidas por antiinflamatorios no esteroidales (AINES), pero la principal indicación y en la cual se hará énfasis es la gineco-obstetrica ya que su actividad uterotónica lo hace eficaz como inductor de parto y como Agente abortivo, usándose principalmente en el primer trimestre de embarazo, administrado por vía oral, vaginal, sublingual, bucal o rectal (2). El uso del misoprostol como inductor de parto ha venido aumentando en los últimos años aunque este no este aún autorizado por varios entes reguladores importantes como la FDA (Food and Drug Administration) y otras agencias internacionales de reglamentación farmacéutica incluyendo el Colegio Real Británico de Obstetras y Ginecólogos, esto debido a que la evidencia disponible sugiere posibles riesgos graves, como la rotura uterina, la mortalidad materna, la mortalidad perinatal y sepsis además de la escasez de datos sobre los riesgos graves de la inducción con este fármaco. Este aumento es debido al fácil acceso de este medicamento y a la poca regulación del mismo, ya que se puede obtener incluso en el domicilio, no se requiere de una prescripción médica y muchas veces existe la sobredosificación porque se cree que a mayor concentración, más efectividad en el tratamiento; estudios han demostrado que una monoterapia de 800mcg de misoprostol intravaginal son efectivos en la mayoría de los casos siempre y cuando la paciente tenga menos de 63 días de gestación (3). Aun así se sigue promoviendo y recomendando deliberadamente la inducción con el misoprostol por varias entidades de salud como profamilia, dejando de lado la cantidad de casos existentes con efectos adversos graves en mujeres entre 19-30 años. Se debe tener mucha precaución con la utilización del misoprostol como inductor de parto ya que puede tener muchas afectaciones de salud como diarrea, aborto incompleto, alergias, entre otras, es necesario cumplir con ciertos requisitos para que el tratamiento sea exitoso además de obtener un buen diagnóstico médico para determinar si se es apto o no para la administración del medicamento. La presente investigación pretende caracterizar esas reacciones adversas tomando como base el programa mundial de farmacovigilancia de la OMS 1985-2019 para luego proponer una pieza comunicativa dirigida a personal de salud y pacientes para la identificación, prevención, tratamiento y reporte de reacciones adversas por uso del MisoprostolMisoprostol is a synthetic analogue of prostaglandin E1, which has several therapeutic indications (1), in some countries it is used as an antiulcer to prevent gastric ulcers induced by non-steroidal anti-inflammatory drugs, but the main indication and in which emphasis is on gyneco-obstetrics since its uterotonic activity makes it effective as a labor inducer and as an Abortive Agent, being used mainly in the first trimester of pregnancy, administered orally, vaginally, sublingually, orally or rectally (2). The use of misoprostol as a labor inducer has been increasing in recent years although it is not yet authorized by several important regulatory entities such as the FDA (Food and Drug Administration) and other international pharmaceutical regulatory agencies including the Royal British College of Obstetricians and Gynecologists, this because the available evidence suggests possible serious risks, such as uterine rupture, maternal mortality, perinatal mortality and sepsis in addition to the lack of data on the serious risks of induction with this drug. This increase is due to the easy access of this medicine and its poor regulation, since it can be obtained even at home, a medical prescription is not required and there is often an overdose because it is believed that the higher the concentration, the more effective in the treatment; studies have shown that an 800mcg monotherapy of intravaginal misoprostol is effective in most cases as long as the patient is less than 63 days pregnant (3). Even so, the induction with misoprostol by several health entities as a family is still being promoted and deliberately recommended, leaving aside the number of existing cases with serious adverse effects in women between 19-30 years. Care should be taken with the use of misoprostol as a labor inducer since it can have many health conditions such as diarrhea, incomplete interuption of pregnancy, allergies, among others, it is necessary to meet certain requirements for the treatment to be successful in addition to obtaining a good medical diagnosis to determine if it is allow to get the medicine. The present research aims to characterize these adverse reactions based on the world pharmacovigilance program of WHO 1985-2019 and then propose a communication piece for all the people for the identification, prevention, treatment of the information and reporting of adverse reactions by using Misoprostol.Incluye bibliografí
-
Reacciones adversas com Misoprostol reportadas al Programa Mundial de Farmacovigilancia de la OMS 1985-2019
Química Farmacéutica, 2020Co-Authors: Ferro Holguín, Laura Natalia, Galindo Ramos, Paula AndreaAbstract:97 páginas : gráficasMisoprostol is a synthetic analogue of prostaglandin E1, which has several therapeutic indications (1), in some countries it is used as an antiulcer to prevent gastric ulcers induced by non-steroidal anti-inflammatory drugs, but the main indication and in which emphasis is on gyneco-obstetrics since its uterotonic activity makes it effective as a labor inducer and as an Abortive Agent, being used mainly in the first trimester of pregnancy, administered orally, vaginally, sublingually, orally or rectally (2). The use of misoprostol as a labor inducer has been increasing in recent years although it is not yet authorized by several important regulatory entities such as the FDA (Food and Drug Administration) and other international pharmaceutical regulatory agencies including the Royal British College of Obstetricians and Gynecologists, this because the available evidence suggests possible serious risks, such as uterine rupture, maternal mortality, perinatal mortality and sepsis in addition to the lack of data on the serious risks of induction with this drug. This increase is due to the easy access of this medicine and its poor regulation, since it can be obtained even at home, a medical prescription is not required and there is often an overdose because it is believed that the higher the concentration, the more effective in the treatment; studies have shown that an 800mcg monotherapy of intravaginal misoprostol is effective in most cases as long as the patient is less than 63 days pregnant (3). Even so, the induction with misoprostol by several health entities as a family is still being promoted and deliberately recommended, leaving aside the number of existing cases with serious adverse effects in women between 19-30 years. Care should be taken with the use of misoprostol as a labor inducer since it can have many health conditions such as diarrhea, incomplete interuption of pregnancy, allergies, among others, it is necessary to meet certain requirements for the treatment to be successful in addition to obtaining a good medical diagnosis to determine if it is allow to get the medicine. The present research aims to characterize these adverse reactions based on the world pharmacovigilance program of WHO 1985-2019 and then propose a communication piece for all the people for the identification, prevention, treatment of the information and reporting of adverse reactions by using Misoprostol.El misoprostol es un análogo sintético de la prostaglandina E1, el cual tiene varias indicaciones terapéuticas (1), en algunos países se utiliza como antiulceroso para prevenir úlceras gástricas inducidas por antiinflamatorios no esteroidales (AINES), pero la principal indicación y en la cual se hará énfasis es la gineco-obstetrica ya que su actividad uterotónica lo hace eficaz como inductor de parto y como Agente abortivo, usándose principalmente en el primer trimestre de embarazo, administrado por vía oral, vaginal, sublingual, bucal o rectal (2). El uso del misoprostol como inductor de parto ha venido aumentando en los últimos años aunque este no este aún autorizado por varios entes reguladores importantes como la FDA (Food and Drug Administration) y otras agencias internacionales de reglamentación farmacéutica incluyendo el Colegio Real Británico de Obstetras y Ginecólogos, esto debido a que la evidencia disponible sugiere posibles riesgos graves, como la rotura uterina, la mortalidad materna, la mortalidad perinatal y sepsis además de la escasez de datos sobre los riesgos graves de la inducción con este fármaco. Este aumento es debido al fácil acceso de este medicamento y a la poca regulación del mismo, ya que se puede obtener incluso en el domicilio, no se requiere de una prescripción médica y muchas veces existe la sobredosificación porque se cree que a mayor concentración, más efectividad en el tratamiento; estudios han demostrado que una monoterapia de 800mcg de misoprostol intravaginal son efectivos en la mayoría de los casos siempre y cuando la paciente tenga menos de 63 días de gestación (3). Aun así se sigue promoviendo y recomendando deliberadamente la inducción con el misoprostol por varias entidades de salud como profamilia, dejando de lado la cantidad de casos existentes con efectos adversos graves en mujeres entre 19-30 años. Se debe tener mucha precaución con la utilización del misoprostol como inductor de parto ya que puede tener muchas afectaciones de salud como diarrea, aborto incompleto, alergias, entre otras, es necesario cumplir con ciertos requisitos para que el tratamiento sea exitoso además de obtener un buen diagnóstico médico para determinar si se es apto o no para la administración del medicamento. La presente investigación pretende caracterizar esas reacciones adversas tomando como base el programa mundial de farmacovigilancia de la OMS 1985-2019 para luego proponer una pieza comunicativa dirigida a personal de salud y pacientes para la identificación, prevención, tratamiento y reporte de reacciones adversas por uso del MisoprostolIncluye bibliografíaPregradoQuímico(a) Farmacéutic
Ferro Holguín, Laura Natalia - One of the best experts on this subject based on the ideXlab platform.
-
Reacciones adversas com Misoprostol reportadas al Programa Mundial de Farmacovigilancia de la OMS 1985-2019
Bogotá : Universidad de Ciencias Aplicadas y Ambientales 2020, 2020Co-Authors: Ferro Holguín, Laura Natalia, Galindo Ramos, Paula AndreaAbstract:97 páginas : gráficasEl misoprostol es un análogo sintético de la prostaglandina E1, el cual tiene varias indicaciones terapéuticas (1), en algunos países se utiliza como antiulceroso para prevenir úlceras gástricas inducidas por antiinflamatorios no esteroidales (AINES), pero la principal indicación y en la cual se hará énfasis es la gineco-obstetrica ya que su actividad uterotónica lo hace eficaz como inductor de parto y como Agente abortivo, usándose principalmente en el primer trimestre de embarazo, administrado por vía oral, vaginal, sublingual, bucal o rectal (2). El uso del misoprostol como inductor de parto ha venido aumentando en los últimos años aunque este no este aún autorizado por varios entes reguladores importantes como la FDA (Food and Drug Administration) y otras agencias internacionales de reglamentación farmacéutica incluyendo el Colegio Real Británico de Obstetras y Ginecólogos, esto debido a que la evidencia disponible sugiere posibles riesgos graves, como la rotura uterina, la mortalidad materna, la mortalidad perinatal y sepsis además de la escasez de datos sobre los riesgos graves de la inducción con este fármaco. Este aumento es debido al fácil acceso de este medicamento y a la poca regulación del mismo, ya que se puede obtener incluso en el domicilio, no se requiere de una prescripción médica y muchas veces existe la sobredosificación porque se cree que a mayor concentración, más efectividad en el tratamiento; estudios han demostrado que una monoterapia de 800mcg de misoprostol intravaginal son efectivos en la mayoría de los casos siempre y cuando la paciente tenga menos de 63 días de gestación (3). Aun así se sigue promoviendo y recomendando deliberadamente la inducción con el misoprostol por varias entidades de salud como profamilia, dejando de lado la cantidad de casos existentes con efectos adversos graves en mujeres entre 19-30 años. Se debe tener mucha precaución con la utilización del misoprostol como inductor de parto ya que puede tener muchas afectaciones de salud como diarrea, aborto incompleto, alergias, entre otras, es necesario cumplir con ciertos requisitos para que el tratamiento sea exitoso además de obtener un buen diagnóstico médico para determinar si se es apto o no para la administración del medicamento. La presente investigación pretende caracterizar esas reacciones adversas tomando como base el programa mundial de farmacovigilancia de la OMS 1985-2019 para luego proponer una pieza comunicativa dirigida a personal de salud y pacientes para la identificación, prevención, tratamiento y reporte de reacciones adversas por uso del MisoprostolMisoprostol is a synthetic analogue of prostaglandin E1, which has several therapeutic indications (1), in some countries it is used as an antiulcer to prevent gastric ulcers induced by non-steroidal anti-inflammatory drugs, but the main indication and in which emphasis is on gyneco-obstetrics since its uterotonic activity makes it effective as a labor inducer and as an Abortive Agent, being used mainly in the first trimester of pregnancy, administered orally, vaginally, sublingually, orally or rectally (2). The use of misoprostol as a labor inducer has been increasing in recent years although it is not yet authorized by several important regulatory entities such as the FDA (Food and Drug Administration) and other international pharmaceutical regulatory agencies including the Royal British College of Obstetricians and Gynecologists, this because the available evidence suggests possible serious risks, such as uterine rupture, maternal mortality, perinatal mortality and sepsis in addition to the lack of data on the serious risks of induction with this drug. This increase is due to the easy access of this medicine and its poor regulation, since it can be obtained even at home, a medical prescription is not required and there is often an overdose because it is believed that the higher the concentration, the more effective in the treatment; studies have shown that an 800mcg monotherapy of intravaginal misoprostol is effective in most cases as long as the patient is less than 63 days pregnant (3). Even so, the induction with misoprostol by several health entities as a family is still being promoted and deliberately recommended, leaving aside the number of existing cases with serious adverse effects in women between 19-30 years. Care should be taken with the use of misoprostol as a labor inducer since it can have many health conditions such as diarrhea, incomplete interuption of pregnancy, allergies, among others, it is necessary to meet certain requirements for the treatment to be successful in addition to obtaining a good medical diagnosis to determine if it is allow to get the medicine. The present research aims to characterize these adverse reactions based on the world pharmacovigilance program of WHO 1985-2019 and then propose a communication piece for all the people for the identification, prevention, treatment of the information and reporting of adverse reactions by using Misoprostol.Incluye bibliografí
-
Reacciones adversas com Misoprostol reportadas al Programa Mundial de Farmacovigilancia de la OMS 1985-2019
Química Farmacéutica, 2020Co-Authors: Ferro Holguín, Laura Natalia, Galindo Ramos, Paula AndreaAbstract:97 páginas : gráficasMisoprostol is a synthetic analogue of prostaglandin E1, which has several therapeutic indications (1), in some countries it is used as an antiulcer to prevent gastric ulcers induced by non-steroidal anti-inflammatory drugs, but the main indication and in which emphasis is on gyneco-obstetrics since its uterotonic activity makes it effective as a labor inducer and as an Abortive Agent, being used mainly in the first trimester of pregnancy, administered orally, vaginally, sublingually, orally or rectally (2). The use of misoprostol as a labor inducer has been increasing in recent years although it is not yet authorized by several important regulatory entities such as the FDA (Food and Drug Administration) and other international pharmaceutical regulatory agencies including the Royal British College of Obstetricians and Gynecologists, this because the available evidence suggests possible serious risks, such as uterine rupture, maternal mortality, perinatal mortality and sepsis in addition to the lack of data on the serious risks of induction with this drug. This increase is due to the easy access of this medicine and its poor regulation, since it can be obtained even at home, a medical prescription is not required and there is often an overdose because it is believed that the higher the concentration, the more effective in the treatment; studies have shown that an 800mcg monotherapy of intravaginal misoprostol is effective in most cases as long as the patient is less than 63 days pregnant (3). Even so, the induction with misoprostol by several health entities as a family is still being promoted and deliberately recommended, leaving aside the number of existing cases with serious adverse effects in women between 19-30 years. Care should be taken with the use of misoprostol as a labor inducer since it can have many health conditions such as diarrhea, incomplete interuption of pregnancy, allergies, among others, it is necessary to meet certain requirements for the treatment to be successful in addition to obtaining a good medical diagnosis to determine if it is allow to get the medicine. The present research aims to characterize these adverse reactions based on the world pharmacovigilance program of WHO 1985-2019 and then propose a communication piece for all the people for the identification, prevention, treatment of the information and reporting of adverse reactions by using Misoprostol.El misoprostol es un análogo sintético de la prostaglandina E1, el cual tiene varias indicaciones terapéuticas (1), en algunos países se utiliza como antiulceroso para prevenir úlceras gástricas inducidas por antiinflamatorios no esteroidales (AINES), pero la principal indicación y en la cual se hará énfasis es la gineco-obstetrica ya que su actividad uterotónica lo hace eficaz como inductor de parto y como Agente abortivo, usándose principalmente en el primer trimestre de embarazo, administrado por vía oral, vaginal, sublingual, bucal o rectal (2). El uso del misoprostol como inductor de parto ha venido aumentando en los últimos años aunque este no este aún autorizado por varios entes reguladores importantes como la FDA (Food and Drug Administration) y otras agencias internacionales de reglamentación farmacéutica incluyendo el Colegio Real Británico de Obstetras y Ginecólogos, esto debido a que la evidencia disponible sugiere posibles riesgos graves, como la rotura uterina, la mortalidad materna, la mortalidad perinatal y sepsis además de la escasez de datos sobre los riesgos graves de la inducción con este fármaco. Este aumento es debido al fácil acceso de este medicamento y a la poca regulación del mismo, ya que se puede obtener incluso en el domicilio, no se requiere de una prescripción médica y muchas veces existe la sobredosificación porque se cree que a mayor concentración, más efectividad en el tratamiento; estudios han demostrado que una monoterapia de 800mcg de misoprostol intravaginal son efectivos en la mayoría de los casos siempre y cuando la paciente tenga menos de 63 días de gestación (3). Aun así se sigue promoviendo y recomendando deliberadamente la inducción con el misoprostol por varias entidades de salud como profamilia, dejando de lado la cantidad de casos existentes con efectos adversos graves en mujeres entre 19-30 años. Se debe tener mucha precaución con la utilización del misoprostol como inductor de parto ya que puede tener muchas afectaciones de salud como diarrea, aborto incompleto, alergias, entre otras, es necesario cumplir con ciertos requisitos para que el tratamiento sea exitoso además de obtener un buen diagnóstico médico para determinar si se es apto o no para la administración del medicamento. La presente investigación pretende caracterizar esas reacciones adversas tomando como base el programa mundial de farmacovigilancia de la OMS 1985-2019 para luego proponer una pieza comunicativa dirigida a personal de salud y pacientes para la identificación, prevención, tratamiento y reporte de reacciones adversas por uso del MisoprostolIncluye bibliografíaPregradoQuímico(a) Farmacéutic
Josee E Leysen - One of the best experts on this subject based on the ideXlab platform.
-
agonistic properties of alniditan sumatriptan and dihydroergotamine on human 5 ht1b and 5 ht1d receptors expressed in various mammalian cell lines
British Journal of Pharmacology, 1998Co-Authors: Anne Simone Josephine Lesage, Walter Luyten, Ria Wouters, Paul Van Gompel, Lieve Heylen, Peter Vanhoenacker, Guy Haegeman, Josee E LeysenAbstract:Alniditan, a novel migraine Abortive Agent, is a potent 5-HT1B/5-HT1D receptor agonist of nM affinity. We compared the agonistic properties of alniditan, sumatriptan and dihydroergotamine on the cloned human 5-HT1B receptor expressed at 200 fmol mg−1 protein (Bmax) in non-induced L929sA cells, at 740 fmol mg−1 protein in HEK 293 and at 2300 fmol mg−1 protein in mIFNβ-induced L929sA cells, and on the human cloned 5-HT1D receptor expressed in C6 glioma cells (Bmax 780 fmol mg−1 protein). Sodium butyrate treatment increased the expression level of human (h)5-HT1B receptors in HEK 293 cells and h5-HT1D receptors in C6 glioma cells approximately 3 fold, the binding affinities of [3H]-5-HT and [3H]-alniditan were unaffected. Agonistic properties were evaluated based on inhibition of cyclic AMP accumulation in the cells after stimulation of adenylyl cyclase by forskolin or isoproterenol. Alniditan, sumatriptan and dihydroergotamine were full agonists at the h5-HT1B receptor (IC50 values were 1.7, 20 and 2 nM, respectively in HEK 293 cells) and h5-HT1D receptors (IC50 values of 1.3, 2.6 and 2.2 nM, respectively). At the h5-HT1B receptor the agonist potency of the compounds slightly increased with higher receptor density. The opposite was seen for antagonists (ocaperidone, risperidone and ritanserin). This comparative study demonstrated that alniditan was 10 times more potent than sumatriptan at the h5-HT1B receptor, and twice as potent at the h5-HT1D receptor. Dihydroergotamine was more potent an agonist at the h5-HT1B receptor when expressed at high and low level in L929sA cells (but not in HEK 293 cells), and was less potent at the h5-HT1D receptor. British Journal of Pharmacology (1998) 123, 1655–1665; doi:10.1038/sj.bjp.0701766
Engels M - One of the best experts on this subject based on the ideXlab platform.
-
Epizootiologic investigations of selected Abortive Agents in free-ranging alpine ibex (capra ibex ibex) in Switzerland
'Wildlife Disease Association', 2011Co-Authors: Marreros N, Frey, Caroline F., Hüssy D, Albini S, Abril C, Vogt H R, Holzwarth N, Wirz-dittus S, Friess M, Engels MAbstract:In the early 2000s, several colonies of Alpine ibex (Capra ibex ibex) in Switzerland ceased growing or began to decrease. Reproductive problems due to infections with Abortive Agents might have negatively affected recruitment. We assessed the presence of selected Agents of abortion in Alpine ibex by serologic, molecular, and culture techniques and evaluated whether infection with these Agents might have affected population densities. Blood and fecal samples were collected from 651 ibex in 14 colonies throughout the Swiss Alps between 2006 and 2008. All samples were negative for Salmonella spp., Neospora caninum, and Bovine Herpesvirus-1. Antibodies to Coxiella burnetii, Leptospira spp., Chlamydophila abortus, Toxoplasma gondii, and Bovine Viral Diarrhea virus were detected in at least one ibex. Positive serologic results for Brucella spp. likely were false. Overall, 73 samples (11.2%) were antibody-positive for at least one Abortive Agent. Prevalence was highest for Leptospira spp. (7.9%, 95% CI55.0–11.7). The low prevalences and the absence of significant differences between colonies with opposite population trends suggest these pathogens do not play a significant role in the population dynamics of Swiss ibex. Alpine ibex do not seem to be a reservoir for these Abortive Agents or an important source of infection for domestic livestock in Switzerland. Finally, although interactions on summer pastures occur frequently, spillover from infected livestock to free-ranging ibex apparently is uncommon. Key words: Abortive Agents, Alpine ibex, Capra ibex ibex, population dynamics, serology,survey, Switzerland
Engels Monika - One of the best experts on this subject based on the ideXlab platform.
-
Epizootiologic investigations of selected Abortive Agents in free-ranging Alpine ibex (Capra ibex ibex) in Switzerland
'Wildlife Disease Association', 2011Co-Authors: Marreros Nelson, Hüssy Daniela, Albini Sarah, Frey, Caroline F., Abril Carlos, Vogt Hans-rudolf, Holzwarth Nathalie, Wirz-dittus Sophie, Friess Martina, Engels MonikaAbstract:In the early 2000s, several colonies of Alpine ibex (Capra ibex ibex) in Switzerland ceased growing or began to decrease. Reproductive problems due to infections with Abortive Agents might have negatively affected recruitment. We assessed the presence of selected Agents of abortion in Alpine ibex by serologic, molecular, and culture techniques and evaluated whether infection with these Agents might have affected population densities. Blood and fecal samples were collected from 651 ibex in 14 colonies throughout the Swiss Alps between 2006 and 2008. All samples were negative for Salmonella spp., Neospora caninum, and Bovine Herpesvirus-1. Antibodies to Coxiella burnetii, Leptospira spp., Chlamydophila abortus, Toxoplasma gondii, and Bovine Viral Diarrhea virus were detected in at least one ibex. Positive serologic results for Brucella spp. likely were false. Overall, 73 samples (11.2%) were antibody-positive for at least one Abortive Agent. Prevalence was highest for Leptospira spp. (7.9%, 95% CI=5.0–11.7). The low prevalences and the absence of significant differences between colonies with opposite population trends suggest these pathogens do not play a significant role in the population dynamics of Swiss ibex. Alpine ibex do not seem to be a reservoir for these Abortive Agents or an important source of infection for domestic livestock in Switzerland. Finally, although interactions on summer pastures occur frequently, spillover from infected livestock to free-ranging ibex apparently is uncommon
